Q-POC is a solar-powered or wind-up handheld tool designed to diagnose, manage, monitor, and track infections and drug resistance. DNA-based diagnostics can be performed at point-of-care in 10-20 minutes with Q-POC. The device also includes GPS-enabled epidemiological surveillance. Q-POC is currently in a prototype stage and is expected to be commercialized soon. Single use test cartridges are being developed for Warfarin dosage, malaria and drug resistance, hospital acquired infections, and tumor profiling.)
Intellectural Property Type
User Provision Model
Unknown, as the product has not been commercialized yet.
Distributions to Date Status
N/A, product commercialization expected 2019
99%, 10 to 50 copies/mL
Sensitivity : No ‘indeterminate’ result
Indispensable equipment for function (Y/N)
Yes, testing cassettes
Maintenance or calibration required by user at time of use? (Y/N)
Number of Tests Performed
The Q-POC can currently generate diagnostics for SARs COV 2
Power supply type: Continuous, Recharging only (V, time required, battery life), Other
and Li-Ion 14.4V / 6.90Ah / 99.40Wh Battery
Time required for procedure (minutes)
approximately 30 minutes
The Q-POC is a portable, battery-operated diagnostics device that can process blood, urine, sputum, tissue, and swabs and delivers results in 10-20 minutes. Results are displayed on a touchscreen and can be stored on the device, sent to a printer, or transferred to a computer or the Cloud via USB or WiFi. Globally distributed Q-POC devices will also geotag and anonymize pathogen data and send to the cloud for real-time disease and drug resistance monitoring. [caption id="attachment_63588" align="alignnone" width="400"] Technical Specifications of Q-POC[/caption] Find the technical specifications here
Provided by the manufacturer
Manufacturer Specified Performance Parameters
QuantuMDx seeks Q-POC can provide personalized medicine, be portable, provide a quick diagnosis, allow for geotagging an creating a network of data.
Vetted Performance Status
99% sensitivity and specificity to molecular results were claimed.
Complementary Technical Systems
Academic Research and References
Dunning, L., Kroon, M., Hsiao, N., and Myer, L., 2017, Field Evaluation of HIV Point-of-Care Testing for Early Infant Diagnosis in Cape Town, South Africa, PloS One, 12(12), p. e0189226.
Vu, C., Chan, J., Todaro, M., Skafidas, S., and Kwan, P., 2015, Point-of-Care Molecular Diagnostic Devices: an Overview, Pharmacogenomics, 16(12), pp. 1399-1409.
Dorman, S., 2015, Advances in the Diagnosis of Tuberculosis: Current Status and Future Prospects, The International Journal of Tuberculosis and Lung Disease, 19(5), pp. 504-516.
Basha, I., Ho, E., 2017, Towards Multiplex Molecular Diagnosis—A Review of Microfluidic Genomics Technologies, Micromachines, 8(9), p. 266.
Compliance with regulations
QuantumDx plans to obtain CE marking for all of the Q-POC tests in the short term and then pursue a 510(k) submission with the US Food and Drug Administration.